Lipitor Diabetes Claimants Continue to Join Federal Litigation, More than 700 Lipitor Lawsuits Now Filed in South Carolina Federal Court, Bernstein Liebhard LLP Reports
The Firm is currently offering free and confidential Lipitor lawsuit evaluations to individuals who may have developed Type 2 diabetes after taking the cholesterol-lowering statin.
New York, NY (PRWEB) May 26, 2014
More than 230 Lipitor lawsuit (http://www.thelipitorlawsuit.com/) filings have been added to a federal litigation established in South Carolina since court documents were last updated in April, Bernstein Liebhard LLP reports.
A Case List issued May 15th by the U.S. Judicial on Multidistrict Litigation (JPML) indicates that 703 claims against Pfizer, Inc. have now been filed in South Carolina federal court. Among other things, federal claims in this proceeding allege that the cholesterol-lowering statin can cause new-onset Type 2 diabetes. The number of cases now pending in the U.S. District Court, District of South Carolina reflects a significant increase compared to a month earlier, when the federal litigation reported 464 claims filed as of April 15. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)
“We are not surprised to see the number of Lipitor lawsuits continuing to increase in the federal litigation, as our Firm continues to hear from individuals who allegedly developed Type 2 diabetes after taking the cholesterol medication,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free and confidential case evaluations to potential Lipitor diabetes claimants.
Approved in 1996 to treat individuals with high cholesterol, Lipitor is a statin medication manufactured by Pfizer, Inc. Claims now filed in the U.S. District Court, District of South Carolina allege that use of the drug may cause the development of Type 2 diabetes, an association that was made public two years ago when the U.S. Food and Drug Administration(FDA) mandated in February 2012 that Pfizer and other statin manufacturers adjust labeling on their products to note the possibility of this side effect. This FDA action was prompted by a study published a month earlier in JAMA: Internal Medicine that found an increased risk for diabetes in post-menopausal women.*
Plaintiffs in more than 700 Lipitor lawsuits allege that the newly-adjusted labeling from Pfizer remains inadequate in warning patients about side effects allegedly associated with the statin.
In May 2013, the British Medical Journal lent further evidence to Lipitor diabetes claims when the results of a study showed a 22 percent increased risk for diabetes in those taking atorvastatin, the generic version of Lipitor.**
Individuals who were diagnosed with Type 2 diabetes after taking Lipitor may be eligible to seek compensation for damages allegedly caused by the cholesterol-lowering statin. Learn more about the association between Lipitor and diabetes by visiting Bernstein Liebhard LLP’s website. To arrange for a free legal review, please call 800-511-5092.
*archinte.jamanetwork.com/article.aspx?articleid=1108676, JAMA Internal Medicine, January 2012
**bmj.com/content/346/bmj.f2610, BMJ, May 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorney fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
For the original version on PRWeb visit: http://www.prweb.com/releases/lipitor-lawsuit/lipitor-diabetes/prweb11881788.htm